サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1794531

強迫性障害治療薬の世界市場

Obsessive-Compulsive Disorder Drugs

出版日
ページ情報
英文 282 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.34円
強迫性障害治療薬の世界市場
出版日: 2025年08月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 282 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

強迫性障害治療薬の世界市場は2030年までに15億米ドルに達する

2024年に11億米ドルと推定される強迫性障害治療薬の世界市場は、2024～2030年の分析期間においてCAGR 5.3%で成長し、2030年には15億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるSSRIは、CAGR 6.2%を記録し、分析期間終了時には9億7,390万米ドルに達すると予測されます。TCAセグメントの成長率は、分析期間中CAGR 3.4%と推定されます。

米国市場は2億9,230万米ドルと推定、中国はCAGR 8.6％で成長予測

米国の強迫性障害治療薬市場は、2024年に2億9,230万米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 8.6%で推移し、2030年には2億9,500万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.5％と5.3％と予測されています。欧州では、ドイツがCAGR 3.4%で成長すると予測されています。

世界の強迫性障害治療薬市場- 主要動向と促進要因まとめ

強迫性障害の治療ニーズは医薬品開発にどのような影響を与えているか？

強迫性障害（OCD）は、日常生活に支障をきたす強迫観念や強迫行為を繰り返す慢性的な精神疾患です。OCDを治療するためには、薬理学的、心理学的介入を組み合わせる必要があります。薬物療法の中では、選択的セロトニン再取り込み阻害薬（SSRI）が第一選択薬であり、フルオキセチン、フルボキサミン、セルトラリンなどが広く処方されています。これらの薬剤は、強迫症状に重要な役割を果たしていると考えられているセロトニンレベルを調節するのに役立ちます。

SSRIはその有効性にもかかわらず、すべての患者にとって普遍的に有益であるわけではなく、多くの患者で部分的な反応や治療抵抗性がみられます。この限界から、特にSSRIの単剤療法が不十分な場合に、リスペリドンやアリピプラゾールのような抗精神病薬を使用するような増強療法への関心が高まっています。より標的を絞った即効性のある治療法の必要性から、グルタミン酸や他の神経伝達経路を調節する新規化合物の製薬研究が続けられています。

選択肢の拡大において、技術革新と研究はどのような役割を果たすのか？

神経薬理学における最近の動向は、OCD治療薬の開発に新たな道を開いています。研究者達はグルタミン酸伝達や炎症に関連した機序を標的とした薬剤を探求しており、従来のセロトニンを中心とした治療法に代わる選択肢を提供しています。研究中の薬剤にはNMDA受容体モジュレーターやドーパミンやノルエピネフリンに作用する再取り込み阻害剤などがあり、これらは現在の治療法に反応しない患者を救済する可能性があります。

ケタミンや気分安定薬などの特定の薬剤の適応外使用も、治療抵抗性の症状を軽減する可能性があるとして研究されています。さらに、患者の生物学的プロファイルに基づいて、より効果的に治療法を適合させるための薬理遺伝学的アプローチも研究されています。これらの技術革新は、OCD治療を個別化し、精神科の薬物治療で一般的に直面する試行錯誤の負担を軽減するための幅広い努力を反映しています。

ヘルスケアシステムとアクセスパターンはどのように市場動向を形成しているのか？

OCD治療薬へのアクセスは、精神科医療サービスの向上やプライマリーケア提供者の認知度向上により拡大しています。OCDと診断される割合が特に青年や若年成人の間で増加するにつれ、タイムリーな薬理学的介入に対する需要が高まっています。新興経済諸国では、国のヘルスケア制度や精神科治療に対する保険適用により、より広範な治療が受けられるようになっています。しかし、低・中所得国では、精神科のインフラが限られており、薬剤の入手が困難であるため、まだ格差が残っています。

遠隔医療やデジタルメンタルヘルスプラットフォームも、特に十分な医療が行き届いていない地域において、患者の精神科医療へのアクセスを改善しています。これらのプラットフォームは服薬管理と服薬コンプライアンスを支援し、患者が治療の継続性を維持できるようにします。製薬会社は、早期介入、副作用管理、服薬アドヒアランスの重要性に関する教育を改善するため、メンタルヘルス・プロバイダーとの協力関係をますます強めています。

強迫性障害治療薬市場の成長は、いくつかの要因によってもたらされます。

診断率の上昇、メンタルヘルスに対する一般市民の意識の高まり、保険適用範囲の拡大などが、薬理学的介入に対する需要の高まりに寄与しています。遠隔精神医療やデジタルヘルスプラットフォームの拡大により、薬や治療支援へのタイムリーなアクセスが容易になっています。神経化学研究の革新はSSRIを超える新薬候補の開発を可能にし、薬理遺伝学的研究はより個別化された治療法の基礎を築きつつあります。また、年齢層や文化的背景を超えた精神科医療の受け入れが進んでいることも、世界の医療システムにおけるOCD治療薬の持続的な需要の伸びを支えています。

セグメント

薬剤クラス別（SSRI、TCA、その他の薬剤クラス）;療法（認知行動療法、増強療法、嫌悪療法、系統的脱感作療法、その他の療法）

調査対象企業の例

  • AbbVie Inc.
  • Allergan plc
  • Amorsa Therapeutics Inc.
  • Apotex Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Biohaven Pharmaceuticals Inc.
  • Cannabis Science Inc.
  • Ceruvia Lifesciences LLC
  • Eli Lilly and Company
  • Lundbeck A/S
  • Octapharma AG
  • Omeros Corporation
  • PharmaTher Holdings Ltd
  • Pfizer Inc.
  • Phytecs
  • Rugen Therapeutics R&D Co. Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals USA, Inc.
  • Wisdom Therapeutics（formerly Evecxia）

AI統合

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37530

Global Obsessive-Compulsive Disorder Drugs Market to Reach US$1.5 Billion by 2030

The global market for Obsessive-Compulsive Disorder Drugs estimated at US$1.1 Billion in the year 2024, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. SSRI, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$973.9 Million by the end of the analysis period. Growth in the TCA segment is estimated at 3.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$292.3 Million While China is Forecast to Grow at 8.6% CAGR

The Obsessive-Compulsive Disorder Drugs market in the U.S. is estimated at US$292.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$295.0 Million by the year 2030 trailing a CAGR of 8.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global Obsessive-Compulsive Disorder Drugs Market - Key Trends & Drivers Summarized

How Are Treatment Needs for OCD Influencing Drug Development?

Obsessive-compulsive disorder (OCD) is a chronic mental health condition characterized by recurring, intrusive thoughts and compulsive behaviors that interfere with daily functioning. Managing OCD often requires a combination of pharmacological and psychological interventions. Among pharmaceutical options, selective serotonin reuptake inhibitors (SSRIs) remain the first-line treatment, with fluoxetine, fluvoxamine, and sertraline being widely prescribed. These drugs help regulate serotonin levels, which are believed to play a key role in obsessive-compulsive symptoms.

Despite their effectiveness, SSRIs are not universally beneficial for all patients, and many experience partial response or treatment resistance. This limitation has led to growing interest in augmentation therapies, such as the use of antipsychotic medications like risperidone and aripiprazole, especially in cases where monotherapy with SSRIs proves inadequate. The need for more targeted, faster-acting treatments continues to drive pharmaceutical research toward novel compounds that modulate glutamate or other neurotransmitter pathways.

What Role Do Innovation and Research Play in Expanding Options?

Recent advancements in neuropharmacology are opening new avenues for OCD drug development. Researchers are exploring agents that target glutamatergic transmission and inflammation-related mechanisms, offering alternatives to traditional serotonin-focused therapies. Drugs under investigation include NMDA receptor modulators and reuptake inhibitors affecting dopamine and norepinephrine, which may provide relief for patients who do not respond well to current options.

Off-label use of certain medications, including ketamine and mood stabilizers, is also being studied for their potential to reduce treatment-resistant symptoms. Moreover, pharmacogenetic approaches are being explored to match patients with therapies more effectively based on their biological profile. These innovations reflect a broader effort to personalize OCD treatment and reduce the trial-and-error burden commonly faced in psychiatric drug therapy.

How Are Healthcare Systems and Access Patterns Shaping Market Trends?

Access to OCD medications is expanding through improved mental health services and better awareness among primary care providers. As OCD diagnosis rates increase, particularly among adolescents and young adults, demand for timely pharmacological intervention is growing. National healthcare programs and insurance coverage for psychiatric treatments are supporting wider access in developed economies. In low- and middle-income countries, however, gaps remain due to limited psychiatric infrastructure and inconsistent drug availability.

Telemedicine and digital mental health platforms are also improving patient access to psychiatric care, especially in underserved regions. These platforms support medication management and compliance, helping patients maintain continuity in treatment. Pharmaceutical companies are increasingly collaborating with mental health providers to improve education around early intervention, side effect management, and the importance of medication adherence.

Growth in the obsessive-compulsive disorder drugs market is driven by several factors.

Rising diagnosis rates, growing public awareness of mental health, and broader insurance coverage are contributing to higher demand for pharmacological interventions. Expansion of telepsychiatry and digital health platforms is facilitating timely access to medications and treatment support. Innovation in neurochemical research is enabling development of novel drug candidates beyond SSRIs, while pharmacogenetic exploration is laying the groundwork for more individualized therapies. Increasing acceptance of psychiatric care across age groups and cultural contexts is also supporting sustained growth in demand for OCD medications across global healthcare systems.

SCOPE OF STUDY:

The report analyzes the Obsessive-Compulsive Disorder Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (SSRI, TCA, Other Drug Classes); Therapy (Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization, Other Therapies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

  • AbbVie Inc.
  • Allergan plc
  • Amorsa Therapeutics Inc.
  • Apotex Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Biohaven Pharmaceuticals Inc.
  • Cannabis Science Inc.
  • Ceruvia Lifesciences LLC
  • Eli Lilly and Company
  • Lundbeck A/S
  • Octapharma AG
  • Omeros Corporation
  • PharmaTher Holdings Ltd
  • Pfizer Inc.
  • Phytecs
  • Rugen Therapeutics R&D Co. Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals USA, Inc.
  • Wisdom Therapeutics (formerly Evecxia)

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Obsessive-Compulsive Disorder Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising OCD Diagnosis Rates Globally Spur Demand for Pharmaceutical Interventions
    • Increased Mental Health Awareness Strengthens Business Case for OCD Drug Development
    • Expansion of Telepsychiatry and Digital Health Platforms Drives Access to OCD Treatment Options
    • Growing Acceptance of Psychiatric Medications Reduces Stigma and Propels OCD Drug Adoption
    • Advancements in Neurobiological Research Accelerate Discovery of Novel OCD Drug Targets
    • Rising Comorbidity of OCD with Depression and Anxiety Expands Addressable Treatment Population
    • Strong Pipeline of Novel Therapies Drives Investor Interest and Market Growth Potential
    • Introduction of Rapid-Acting Therapies Throws the Spotlight on Next-Generation OCD Treatments
    • Growing Preference for SSRIs and SNRIs Sustains Demand in First-Line OCD Therapy Segment
    • Emergence of Glutamate Modulators and NMDA Antagonists Creates New Therapeutic Avenues
    • Increasing Off-Label Use of Antipsychotics Enhances Market Opportunity in Treatment-Resistant OCD
    • Focus on Personalized Psychiatry Generates Demand for Pharmacogenomic-Guided OCD Treatments
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Obsessive-Compulsive Disorder Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Obsessive-Compulsive Disorder Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for SSRI by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for SSRI by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for SSRI by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for TCA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for TCA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for TCA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Cognitive Behavioral Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Cognitive Behavioral Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Cognitive Behavioral Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Augmentation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Augmentation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Augmentation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Aversion Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Aversion Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Aversion Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Systematic Desensitization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Systematic Desensitization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Systematic Desensitization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Obsessive-Compulsive Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • JAPAN
    • Obsessive-Compulsive Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • CHINA
    • Obsessive-Compulsive Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: China 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • EUROPE
    • Obsessive-Compulsive Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Obsessive-Compulsive Disorder Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • FRANCE
    • Obsessive-Compulsive Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: France 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • GERMANY
    • Obsessive-Compulsive Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Obsessive-Compulsive Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Obsessive-Compulsive Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Obsessive-Compulsive Disorder Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Obsessive-Compulsive Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • INDIA
    • Obsessive-Compulsive Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: India 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Obsessive-Compulsive Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Obsessive-Compulsive Disorder Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Obsessive-Compulsive Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Obsessive-Compulsive Disorder Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030
  • AFRICA
    • Obsessive-Compulsive Disorder Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Obsessive-Compulsive Disorder Drugs by Drug Class - SSRI, TCA and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Drug Class - Percentage Breakdown of Value Sales for SSRI, TCA and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Obsessive-Compulsive Disorder Drugs by Therapy - Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Obsessive-Compulsive Disorder Drugs by Therapy - Percentage Breakdown of Value Sales for Cognitive Behavioral Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization and Other Therapies for the Years 2014, 2025 & 2030

IV. COMPETITION